Physician profile
Wade T Hunt
NPI 1356339592
$4,177.73
in general payments reported to CMS, 2019-2025
29 companies · $195 in 2025
The $195 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $995 · 2020: $467 · 2021: $733 · 2022: $759 · 2023: $713 · 2024: $316 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,223.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $655.54 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $440.80 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $430.43 | 2019-2024 | |
| Glaxosmithkline, LLC. | $337.12 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $301.48 | 2019-2024 | Ofev |
| Pfizer INC. | $298.20 | 2019-2023 | |
| Amgen INC. | $222.75 | 2019-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.22 | 2019-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $206.18 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $198.26 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $120.33 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $118.67 | 2019-2024 | Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $99.17 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $83.29 | 2021-2022 | |
| Amarin Pharma, INC. | $62.92 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $57.97 | 2023 | Vyepti |
| Alk-Abello, INC | $38.97 | 2025 | Neffy, Odactra, Ragwitek |
| Ibsa Pharma INC. | $38.49 | 2023 | Tirosint, Licart |
| Bayer Healthcare Pharmaceuticals INC. | $32.68 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.79 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $27.93 | 2020 | |
| Sanofi-Aventis U.S. LLC | $27.78 | 2025 | |
| Sanofi Pasteur INC. | $22.02 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.38 | 2022 | |
| Horizon Therapeutics Plc | $20.89 | 2021 | |
| Phathom Pharmaceuticals, INC. | $18.86 | 2024 | Voquezna |
| Ani Pharmaceuticals, INC. | $17.71 | 2025 | Purified Cortrophin Gel |
| Tolmar, INC. | $15.42 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wade Hunt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.